H.C. Wainwright Reaffirms Their Buy Rating on Unum Therapeutics Inc (UMRX)

By Carrie Williams

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Unum Therapeutics Inc (UMRXResearch Report), with a price target of $18. The company’s shares closed yesterday at $3.21, close to its 52-week low of $3.03.

Fein commented:

“Our price target of $18/share is based on an equally-weighted composite of: (a) $18.2/share, as a 25x multiple of taxed and diluted $7.75 discounted back to FY19 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $17.3/share (discounted cash flow analysis using a 18% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).”

According to TipRanks.com, Fein is a 3-star analyst with an average return of 2.1% and a 40.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Unum Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $14.

See today’s analyst top recommended stocks >>

Based on Unum Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $11.69 million. In comparison, last year the company had a GAAP net loss of $6.75 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies.